SpyGlass Pharma is an Aliso Viejo, CA-based ophthalmic biotech developing a sustained‑release drug delivery platform to deliver three years of bimatoprost to targeted ocular tissues. The company completed enrollment in a Phase I/II study in the United States and continues to follow first‑in‑human patients over time. SpyGlass plans to share 24‑month follow‑up data at the American Academy of Ophthalmology meeting later this year. It intends to begin two registrational Phase III trials later this year and to work closely with the U.S. Food and Drug Administration to advance the program through Phase III toward commercial approval. The company is led by President Dr. Malik Y. Kahook and CEO Patrick Mooney. Its recent $75M Series D financing will support advancement of the platform through the readout of the two planned registrational Phase III trials. SpyGlass Pharma is an Aliso Viejo, CA-based ophthalmic therapeutics company developing an IOL-mounted, controlled-release drug delivery platform capable of delivering multiple years of therapy. The company was co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman, and is led by CEO Patrick Mooney. Its technology was developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado School of Medicine and was spun out post-Series A funding from New Enterprise Associates. SpyGlass intends to use the proceeds from the Series C to support multiple U.S. clinical trials of its drug delivery platform. The platform is designed to provide controlled release of therapeutics over multiple years. The company recently raised $90M in a Series C financing to advance its clinical programs.

Total raised

$165M

Funding rounds

2

Latest round

Series D

Latest activity

Jun 2025